- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07591337
SNRK & Vascular Endothelial Aging
12. maj 2026 opdateret af: Xintong Ge, Tianjin Medical University
The Association Between SNRK and Vascular Endothelial Aging
Cardiovascular diseases pose a serious threat to public health, and their prevalence is on the rise year by year.
Vascular aging is an independent risk factor for cardiovascular diseases, and endothelial cell senescence is an early event in vascular aging.
Its occurrence can lead to endothelium-dependent vasodilation dysfunction, reduced vascular permeability, and the release of the senescence-associated secretory phenotype (SASP).
These vascular pathological changes further damage the vascular media, leading to vascular remodeling and reduced compliance, accelerating the progression of atherosclerosis, and ultimately resulting in cardiovascular diseases such as coronary heart disease and hypertension.
Recent research of the investigators has revealed that SNRK, a new member of the AMPK family of cellular energy sensors, plays a key regulatory role in vascular development.
Based on this finding, the investigators propose the scientific hypothesis that SNRK responds to both physiological and pathological aging stimuli through differential mechanisms and regulates the process of endothelial cell senescence.
In this study, the investigators will explore the correlation between SNRKAS and carotid vascular structure and endothelial function by measuring the levels of the SNRK upstream lncRNA (SNRKAS) in participants' peripheral blood, in conjunction with carotid ultrasound examinations.
The findings will provide a solid scientific basis for elucidating new mechanisms underlying the onset and progression of vascular aging and for identifying novel therapeutic targets.
Studieoversigt
Status
Rekruttering
Betingelser
Intervention / Behandling
Undersøgelsestype
Observationel
Tilmelding (Anslået)
180
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Xintong Ge, M.D.
- Telefonnummer: 86-022-60362237
- E-mail: xge@tmu.edu.cn
Studiesteder
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Kina, 300052
- Rekruttering
- Tianjin Medical University General Hospital
-
Kontakt:
- Xintong Ge, M.D.
- E-mail: xge@tmu.edu.cn
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Ja
Prøveudtagningsmetode
Sandsynlighedsprøve
Studiebefolkning
Estimated by statistical analysis, a total of 180 subjects were included from individuals who come for physical examinations or medical visits to the leading and collaborating administrations of this project, and meet the inclusion criteria between April 2026 and March 2029.
Beskrivelse
Inclusion Criteria:
- Aged 18-80 years, with the capacity to make decisions independently or represented by an authorized legal guardian;
- Able to provide complete personal information, medical history, and lifestyle history (e.g., smoking and alcohol consumption history);
- No history of severe cardiovascular disease, and deemed eligible for inclusion by a physician.
Exclusion Criteria:
- Women who are pregnant or may become pregnant;
- Patients with a history of neurological disorders, tumors, severe cardiovascular or pulmonary disease, liver failure, kidney failure, or blood disorders;
- Patients who have undergone carotid stenting, carotid endarterectomy, or other similar procedures, or who have unilateral carotid artery occlusion due to any cause;
- Patients who have participated in another clinical trial within the past 4 weeks;
- Individuals deemed unsuitable for this clinical trial by the investigators.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
< 40 years old
Participants of < 40 years old.
|
|
|
40-60 years old
Participants of 40-60 years old.
|
|
|
> 60 years old
Participants of > 60 years old.
|
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Serum levels of SNRKAS detected by RT-PCR
Tidsramme: At enrollment
|
serum levels of SNRKAS (fold change)
|
At enrollment
|
|
Degree of bilateral carotid artery stenosis detected by Doppler ultrasound
Tidsramme: At enrollment
|
Intima-media thickness (mm) and lumen diameter (mm) of bilateral common carotid artery and internal carotid artery
|
At enrollment
|
|
Pulse wave velocity in both carotid arteries detected by Doppler ultrasound
Tidsramme: At enrollment
|
Peak systolic velocity (cm/s) of bilateral common carotid artery and internal carotid artery
|
At enrollment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood lipids levels detected by automated biochemical analyzer (LABOSPECT 008, Hitachi)
Tidsramme: At enrollment
|
Total Cholesterol (mmol/L), Triglycerides (mmol/L), High-Density Lipoprotein (mmol/L), Low-Density Lipoprotein (mmol/L)
|
At enrollment
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Studiestol: Minghui Zou, Ph.D., mhzou@tmu.edu.cn
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. maj 2026
Primær færdiggørelse (Anslået)
30. april 2029
Studieafslutning (Anslået)
30. april 2029
Datoer for studieregistrering
Først indsendt
6. maj 2026
Først indsendt, der opfyldte QC-kriterier
12. maj 2026
Først opslået (Faktiske)
15. maj 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
15. maj 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
12. maj 2026
Sidst verificeret
1. maj 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IRB2026-YX-172-01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
JA
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .